168 related articles for article (PubMed ID: 35086926)
1. Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study.
Lee YC; King MT; O'Connell RL; Lanceley A; Joly F; Hilpert F; Davis A; Roncolato FT; Okamoto A; Bryce J; Donnellan P; Oza AM; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Feeney A; Kaminsky MC; Diamante K; Stockler MR; Friedlander ML;
Int J Gynecol Cancer; 2022 Jun; 32(6):761-768. PubMed ID: 35086926
[TBL] [Abstract][Full Text] [Related]
2. Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.
King MT; Stockler MR; O'Connell RL; Buizen L; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Sehouli J; Feeney A; Berton-Rigaud D; Costa DSJ; Friedlander ML;
Qual Life Res; 2018 Jan; 27(1):59-74. PubMed ID: 29248998
[TBL] [Abstract][Full Text] [Related]
3. Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
Campbell R; Costa DSJ; Stockler MR; Lee YC; Ledermann JA; Berton D; Sehouli J; Roncolato FT; Connell RO; Okamoto A; Bryce J; Oza AM; Avall-Lundqvist E; Berek JS; Lanceley A; Joly F; Hilpert F; Feeney A; Kaminsky MC; Diamante K; Friedlander ML; King MT;
Gynecol Oncol; 2022 Aug; 166(2):254-262. PubMed ID: 35718565
[TBL] [Abstract][Full Text] [Related]
4. Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study.
Friedlander ML; Stockler M; O'Connell R; Voysey M; Oza A; Gillies K; Donovan H; Martyn J; Sjoquist K; Butow P; King MT;
Int J Gynecol Cancer; 2014 Jun; 24(5):857-64. PubMed ID: 24844219
[TBL] [Abstract][Full Text] [Related]
5. Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS).
Roncolato FT; O'Connell RL; Joly F; Lanceley A; Hilpert F; Buizen L; Okamoto A; Aotani E; Salutari V; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Fehm T; Ledermann J; Roemer-Becuwe C; Stockler MR; King MT; Friedlander ML
Gynecol Oncol; 2020 Jan; 156(1):45-53. PubMed ID: 31836184
[TBL] [Abstract][Full Text] [Related]
6. Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer.
King MT; Stockler MR; Butow P; O'Connell R; Voysey M; Oza AM; Gillies K; Donovan HS; Mercieca-Bebber R; Martyn J; Sjoquist K; Friedlander ML
Int J Gynecol Cancer; 2014 Jun; 24(5):865-73. PubMed ID: 24844220
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
8. Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
Roncolato F; King MT; O'Connell RL; Lee YC; Joly F; Hilpert F; Lanceley A; Yoshida Y; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Kaminsky MC; Stockler MR; Friedlander M
Gynecol Oncol; 2024 Feb; 185():128-137. PubMed ID: 38412736
[TBL] [Abstract][Full Text] [Related]
9. Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.
Roncolato FT; Joly F; O'Connell R; Lanceley A; Hilpert F; Buizen L; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Heitz F; Feeney A; Berton-Rigaud D; Stockler MR; King M; Friedlander M;
Oncologist; 2017 Sep; 22(9):1117-1124. PubMed ID: 28596446
[TBL] [Abstract][Full Text] [Related]
10. Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit study.
Sjoquist KM; Friedlander ML; O'Connell RL; Voysey M; King MT; Stockler MR; Oza AM; Gillies K; Martyn JK; Butow PN
Oncologist; 2013; 18(11):1221-8. PubMed ID: 24107972
[TBL] [Abstract][Full Text] [Related]
11. Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
Roncolato FT; Berton-Rigaud D; O'Connell R; Lanceley A; Sehouli J; Buizen L; Okamoto A; Aotani E; Lorusso D; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Hilpert F; Ledermann JA; Kaminsky MC; Stockler MR; King MT; Friedlander M
Gynecol Oncol; 2018 Jan; 148(1):36-41. PubMed ID: 29107348
[TBL] [Abstract][Full Text] [Related]
12. Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer.
Piccirillo MC; Scambia G; Bologna A; Signoriello S; Vergote I; Baumann K; Lorusso D; Murgia V; Sorio R; Ferrandina G; Sacco C; Cormio G; Breda E; Cinieri S; Natale D; Mangili G; Pisano C; Cecere SC; Di Napoli M; Salutari V; Raspagliesi F; Arenare L; Bergamini A; Bryce J; Daniele G; Gallo C; Pignata S; Perrone F
Ann Oncol; 2018 May; 29(5):1189-1194. PubMed ID: 29462248
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
14. The prognostic and predictive role of pain before systemic chemotherapy in recurrent ovarian cancer: an individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) of 1226 patients.
Woopen H; Richter R; Inci G; Alavi S; Chekerov R; Sehouli J
Support Care Cancer; 2020 Apr; 28(4):1997-2003. PubMed ID: 31385100
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.
Stockler MR; Hilpert F; Friedlander M; King MT; Wenzel L; Lee CK; Joly F; de Gregorio N; Arranz JA; Mirza MR; Sorio R; Freudensprung U; Sneller V; Hales G; Pujade-Lauraine E
J Clin Oncol; 2014 May; 32(13):1309-16. PubMed ID: 24687829
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
17. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer.
Doyle C; Crump M; Pintilie M; Oza AM
J Clin Oncol; 2001 Mar; 19(5):1266-74. PubMed ID: 11230467
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
19. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
Musoro JZ; Coens C; Greimel E; King MT; Sprangers MAG; Nordin A; van Dorst EBL; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A;
Gynecol Oncol; 2020 Nov; 159(2):515-521. PubMed ID: 32972782
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
